Silvia Colucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silvia Colucci has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Martina U. Muckenthaler
Center For Translational Biomedical Iron Research, Department of Pediatric Hematology, Oncology Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.
10 shared publications - Matthias W. Hentze
European Molecular Biology Laboratory, 69117 Heidelberg, Germany
5 shared publications - Oriana Marques
Department of Pediatric Oncology, Hematology and Immunology and Hopp Children Cancer Center (KiTZ), University Hospital Heidelberg, Heidelberg, Germany
5 shared publications - Sandro Altamura
Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
5 shared publications - Laura Silvestri
Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology IRCCS Ospedale San Raffaele Milan Italy
4 shared publications Oriana Marques
Department of Pediatric Hematology, Oncology and Immunology - University of Heidelberg, Heidelberg, Germany.; Molecular Medicine Partnership Unit, EMBL and University of Heidelberg, Heidelberg, Germany
4 shared publications
Latest Publications
- Open Access
Identification of RNA Targets of Classical and Non-Canonical RNA-binding Proteins by soniCLIP
Crosslinking and immunoprecipitation followed by sequencing (CLIP-seq) is widely used to identify the RNA targets of RNA-binding proteins (RBPs). However, its application to non-canonical RBPs lacking canonical RNA-binding domains and frequently displaying low or transient RNA occupancy, is limited by low signal-to-noise ratios, high input requirements and error-prone ligation steps during library preparation. To overcome these limitations, we developed soniCLIP, a streamlined CLIP-seq workflow that replaces RNase-mediated RNA fragmentation with sonication and uses a ligation-free strategy for library construction. soniCLIP is optimized for reproducible identification of enriched RBP-associated RNA regions from limited starting material. We benchmarked soniCLIP against the widespread eCLIP approach and observed reproducible recovery of known RBP-associated regions and target recovery comparable to ENCODE eCLIP, while requiring only 10% (500 ug) of protein input. We further applied soniCLIP to the glycolytic enzyme and non-canonical RBP pyruvate kinase M2 (PKM2). We identified 197 significantly enriched RNA regions and validated selected targets by RIP-qRT-PCR and in vitro binding assays. By combining reduced input requirements, high reproducibility, a shortened 3.5-day workflow and the elimination of gel-based purification, soniCLIP provides an efficient and robust approach for the identification of RNA targets of canonical and non canonical RBPs.
Open AccessIdentification of RNA Targets of Classical and Non-Canonical RNA-binding Proteins by soniCLIP
Crosslinking and immunoprecipitation followed by sequencing (CLIP-seq) is widely used to identify the RNA targets of RNA-binding proteins (RBPs). However, its application to non-canonical RBPs lacking canonical RNA-binding domains and frequently displaying low or transient RNA occupancy, is limited by low signal-to-noise ratios, high input requirements and error-prone ligation steps during library preparation. To overcome these limitations, we developed soniCLIP, a streamlined CLIP-seq workflow that replaces RNase-mediated RNA fragmentation with sonication and uses a ligation-free strategy for library construction. soniCLIP is optimized for reproducible identification of enriched RBP-associated RNA regions from limited starting material. We benchmarked soniCLIP against the widespread eCLIP approach and observed reproducible recovery of known RBP-associated regions and target recovery comparable to ENCODE eCLIP, while requiring only 10% (500 ug) of protein input. We further applied soniCLIP to the glycolytic enzyme and non-canonical RBP pyruvate kinase M2 (PKM2). We identified 197 significantly enriched RNA regions and validated selected targets by RIP-qRT-PCR and in vitro binding assays. By combining reduced input requirements, high reproducibility, a shortened 3.5-day workflow and the elimination of gel-based purification, soniCLIP provides an efficient and robust approach for the identification of RNA targets of canonical and non canonical RBPs.
- Open Access
- 3 April 2025
- Published by Wiley in HemaSphere
- Vol. 9 (4) , e70096
Hepatocyte Toll‐like receptors contribute to the hepcidin inflammatory response to pathogens and pathogen‐derived ligands
Iron restriction is a critical pathomechanism underlying the Anemia of Inflammation and an innate immune response limiting the replication of extracellular pathogens. During infections, innate immune cells detect pathogen‐associated molecular patterns (PAMPs) and produce proinflammatory cytokines. Among these, interleukin (IL)‐6 is detected by hepatocytes, where it activates the production of the iron‐regulated hormone hepcidin that inhibits iron export from macrophages. Consequently, macrophages accumulate iron and hypoferremia (low plasma iron) develops. Whether Toll‐like receptors (TLRs) expressed on hepatocytes directly recognize PAMPs and contribute to hepcidin upregulation is still an open question. Stimulation of primary murine hepatocytes with a panel of PAMPs targeting TLRs 1–9 revealed that the TLR5 ligand flagellin and the TLR2:TLR6 ligand FSL1 upregulated hepcidin. Hepcidin was also induced upon treatment with heat‐killed Staphylococcus aureus (HKSA) and Brucella abortus (HKBA). The hepcidin response to flagellin, FSL1, HKSA, and HKBA started at an early time point, was independent of autocrine regulation by IL‐6, and occurred through the TLR‐mitogen‐activated protein kinase (MAPK) axis. By analyzing a macrophage:hepatocyte co‐culture, we additionally show that the hepcidin response was dependent on TLR2:TLR6 expression in hepatocytes and independent of macrophage cytokine secretion. Ex vivo liver perfusion of mice with FSL1 and HKSA further revealed that PAMPs and pathogens can pass the sinusoidal barrier and reach hepatocytes to cause hepcidin upregulation in a TLR2:TLR6‐dependent manner. We conclude that hepatocytes can directly recognize PAMPs and pathogens and promote hepcidin upregulation in a macrophage and cytokine‐independent manner. This positions hepatocytes in the spotlight as potential direct drivers of iron restriction.
- 3 April 2025
- Published by Wiley in HemaSphere
- Vol. 9 (4) , e70096
Open AccessHepatocyte Toll‐like receptors contribute to the hepcidin inflammatory response to pathogens and pathogen‐derived ligands
Iron restriction is a critical pathomechanism underlying the Anemia of Inflammation and an innate immune response limiting the replication of extracellular pathogens. During infections, innate immune cells detect pathogen‐associated molecular patterns (PAMPs) and produce proinflammatory cytokines. Among these, interleukin (IL)‐6 is detected by hepatocytes, where it activates the production of the iron‐regulated hormone hepcidin that inhibits iron export from macrophages. Consequently, macrophages accumulate iron and hypoferremia (low plasma iron) develops. Whether Toll‐like receptors (TLRs) expressed on hepatocytes directly recognize PAMPs and contribute to hepcidin upregulation is still an open question. Stimulation of primary murine hepatocytes with a panel of PAMPs targeting TLRs 1–9 revealed that the TLR5 ligand flagellin and the TLR2:TLR6 ligand FSL1 upregulated hepcidin. Hepcidin was also induced upon treatment with heat‐killed Staphylococcus aureus (HKSA) and Brucella abortus (HKBA). The hepcidin response to flagellin, FSL1, HKSA, and HKBA started at an early time point, was independent of autocrine regulation by IL‐6, and occurred through the TLR‐mitogen‐activated protein kinase (MAPK) axis. By analyzing a macrophage:hepatocyte co‐culture, we additionally show that the hepcidin response was dependent on TLR2:TLR6 expression in hepatocytes and independent of macrophage cytokine secretion. Ex vivo liver perfusion of mice with FSL1 and HKSA further revealed that PAMPs and pathogens can pass the sinusoidal barrier and reach hepatocytes to cause hepcidin upregulation in a TLR2:TLR6‐dependent manner. We conclude that hepatocytes can directly recognize PAMPs and pathogens and promote hepcidin upregulation in a macrophage and cytokine‐independent manner. This positions hepatocytes in the spotlight as potential direct drivers of iron restriction.
- Top Cited PapersOpen Access
- 20 February 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (8) , 866-880
Inflammation-driven NF-κB signaling represses ferroportin transcription in macrophages via HDAC1 and HDAC3
Anemia of inflammation is a prevalent comorbidity in patients with chronic inflammatory disorders. Inflammation causes hypoferremia and iron-restricted erythropoiesis by limiting ferroportin (FPN)–mediated iron export from macrophages that recycle senescent erythrocytes. Macrophage cell surface expression of FPN is reduced by hepcidin-induced degradation and/or by repression of FPN (Slc40a1) transcription via cytokine and Toll-like receptor (TLR) stimulation. Although the mechanisms underlying hepcidin-mediated control of FPN have been extensively studied, those inhibiting Slc40a1 messenger RNA (mRNA) expression remain unknown. We applied targeted RNA interference and pharmacological screens in macrophages stimulated with the TLR2/6 ligand FSL1 and identified critical signaling regulators of Slc40a1 mRNA repression downstream of TLRs and NF-κB signaling. Interestingly, the NF-κB regulatory hub is equally relevant for Slc40a1 mRNA repression driven by the TLR4 ligand lipopolysaccharide, the cytokine tumor necrosis factor β/lymphotoxin-alpha (LTA), and heat-killed bacteria. Mechanistically, macrophage stimulation with heat-killed Staphylococcus aureus recruits the histone deacetylases (HDACs) HDAC1 and HDAC3 to the antioxidant response element (ARE) located in the Slc40a1 promoter. Accordingly, pretreatment with a pan-HDAC inhibitor abrogates Slc40a1 mRNA repression in response to inflammatory cues, suggesting that HDACs act downstream of NF-κB to repress Slc40a1 transcription. Consistently, recruitment of HDAC1 and HDAC3 to the Slc40a1 ARE after stimulation with heat-killed S aureus is dependent on NF-κB signaling. These results support a model in which the ARE integrates the transcriptional responses of Slc40a1 triggered by signals from redox, metabolic, and inflammatory pathways. This work identifies the long-sought mechanism of Slc40a1 transcriptional downregulation upon inflammation, paving the way for therapeutic interventions at this critical juncture.
- 20 February 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (8) , 866-880
Top Cited PapersOpen AccessInflammation-driven NF-κB signaling represses ferroportin transcription in macrophages via HDAC1 and HDAC3
Anemia of inflammation is a prevalent comorbidity in patients with chronic inflammatory disorders. Inflammation causes hypoferremia and iron-restricted erythropoiesis by limiting ferroportin (FPN)–mediated iron export from macrophages that recycle senescent erythrocytes. Macrophage cell surface expression of FPN is reduced by hepcidin-induced degradation and/or by repression of FPN (Slc40a1) transcription via cytokine and Toll-like receptor (TLR) stimulation. Although the mechanisms underlying hepcidin-mediated control of FPN have been extensively studied, those inhibiting Slc40a1 messenger RNA (mRNA) expression remain unknown. We applied targeted RNA interference and pharmacological screens in macrophages stimulated with the TLR2/6 ligand FSL1 and identified critical signaling regulators of Slc40a1 mRNA repression downstream of TLRs and NF-κB signaling. Interestingly, the NF-κB regulatory hub is equally relevant for Slc40a1 mRNA repression driven by the TLR4 ligand lipopolysaccharide, the cytokine tumor necrosis factor β/lymphotoxin-alpha (LTA), and heat-killed bacteria. Mechanistically, macrophage stimulation with heat-killed Staphylococcus aureus recruits the histone deacetylases (HDACs) HDAC1 and HDAC3 to the antioxidant response element (ARE) located in the Slc40a1 promoter. Accordingly, pretreatment with a pan-HDAC inhibitor abrogates Slc40a1 mRNA repression in response to inflammatory cues, suggesting that HDACs act downstream of NF-κB to repress Slc40a1 transcription. Consistently, recruitment of HDAC1 and HDAC3 to the Slc40a1 ARE after stimulation with heat-killed S aureus is dependent on NF-κB signaling. These results support a model in which the ARE integrates the transcriptional responses of Slc40a1 triggered by signals from redox, metabolic, and inflammatory pathways. This work identifies the long-sought mechanism of Slc40a1 transcriptional downregulation upon inflammation, paving the way for therapeutic interventions at this critical juncture.
- 1 November 2023
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 325 (5) , G453-G457
Iron homeostasis in mice: does liver lobe matter?
This study reveals that, despite being structurally separated, liver lobes from C57BL/6 wild-type and iron-overloaded mice can be used interchangeably for the evaluation of iron content and expression of iron-related genes.
- 1 November 2023
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 325 (5) , G453-G457
Iron homeostasis in mice: does liver lobe matter?
This study reveals that, despite being structurally separated, liver lobes from C57BL/6 wild-type and iron-overloaded mice can be used interchangeably for the evaluation of iron content and expression of iron-related genes.
- Open Access
- 18 May 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (8) , 1223-1235
FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes
The expression of the iron regulatory hormone hepcidin in hepatocytes is regulated by the BMP‐SMAD pathway through the type I receptors ALK2 and ALK3, the type II receptors ACVR2A and BMPR2, and the ligands BMP2 and BMP6. We previously identified the immunophilin FKBP12 as a new hepcidin inhibitor that acts by blocking ALK2. Both the physiologic ALK2 ligand BMP6 and the immunosuppressive drug Tacrolimus (TAC) displace FKBP12 from ALK2 and activate the signaling. However, the molecular mechanism whereby FKBP12 regulates BMP‐SMAD pathway activity and thus hepcidin expression remains unclear. Here, we show that FKBP12 acts by modulating BMP receptor interactions and ligand responsiveness. We first demonstrate that in primary murine hepatocytes TAC regulates hepcidin expression exclusively via FKBP12. Downregulation of the BMP receptors reveals that ALK2, to a lesser extent ALK3, and ACVR2A are required for hepcidin upregulation in response to both BMP6 and TAC. Mechanistically, TAC and BMP6 increase ALK2 homo‐oligomerization and ALK2–ALK3 hetero‐oligomerization and the interaction between ALK2 and the type II receptors. By acting on the same receptors, TAC and BMP6 cooperate in BMP pathway activation and hepcidin expression both in vitro and in vivo. Interestingly, the activation state of ALK3 modulates its interaction with FKBP12, which may explain the cell‐specific activity of FKBP12. Overall, our results identify the mechanism whereby FKBP12 regulates the BMP‐SMAD pathway and hepcidin expression in hepatocytes, and suggest that FKBP12–ALK2 interaction is a potential pharmacologic target in disorders caused by defective BMP‐SMAD signaling and characterized by low hepcidin and high BMP6 expression.
- 18 May 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (8) , 1223-1235
Open AccessFKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes
The expression of the iron regulatory hormone hepcidin in hepatocytes is regulated by the BMP‐SMAD pathway through the type I receptors ALK2 and ALK3, the type II receptors ACVR2A and BMPR2, and the ligands BMP2 and BMP6. We previously identified the immunophilin FKBP12 as a new hepcidin inhibitor that acts by blocking ALK2. Both the physiologic ALK2 ligand BMP6 and the immunosuppressive drug Tacrolimus (TAC) displace FKBP12 from ALK2 and activate the signaling. However, the molecular mechanism whereby FKBP12 regulates BMP‐SMAD pathway activity and thus hepcidin expression remains unclear. Here, we show that FKBP12 acts by modulating BMP receptor interactions and ligand responsiveness. We first demonstrate that in primary murine hepatocytes TAC regulates hepcidin expression exclusively via FKBP12. Downregulation of the BMP receptors reveals that ALK2, to a lesser extent ALK3, and ACVR2A are required for hepcidin upregulation in response to both BMP6 and TAC. Mechanistically, TAC and BMP6 increase ALK2 homo‐oligomerization and ALK2–ALK3 hetero‐oligomerization and the interaction between ALK2 and the type II receptors. By acting on the same receptors, TAC and BMP6 cooperate in BMP pathway activation and hepcidin expression both in vitro and in vivo. Interestingly, the activation state of ALK3 modulates its interaction with FKBP12, which may explain the cell‐specific activity of FKBP12. Overall, our results identify the mechanism whereby FKBP12 regulates the BMP‐SMAD pathway and hepcidin expression in hepatocytes, and suggest that FKBP12–ALK2 interaction is a potential pharmacologic target in disorders caused by defective BMP‐SMAD signaling and characterized by low hepcidin and high BMP6 expression.
- Open Access
- 27 September 2022
- Published by Wiley in HemaSphere
- Vol. 6 (10) , e773
Iron-dependent BMP6 Regulation in Liver Sinusoidal Endothelial Cells Is Instructed by Hepatocyte-derived Secretory Signals
- 27 September 2022
- Published by Wiley in HemaSphere
- Vol. 6 (10) , e773
Open AccessIron-dependent BMP6 Regulation in Liver Sinusoidal Endothelial Cells Is Instructed by Hepatocyte-derived Secretory Signals
- Open Access
- 3 March 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (9) , 1418-1422
Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction
Muckenthaler et al describe a novel form of hemochromatosis caused by a constitutional PIGA mutation in 3 children with associated neurologic dysfunction. Hemochromatosis results from decreased hepcidin, which is regulated by HFE, hemojuvelin (HJV), and transferrin receptor 2. HJV is a glycosylphosphatidylinositol-linked protein, so PIGA mutation leads to decreased HJV expression. Interestingly, none of the children had evidence of paroxysmal nocturnal hemoglobinuria. The cause of the novel association with central nervous system manifestations remains to be elucidated.
- 3 March 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (9) , 1418-1422
Open AccessConstitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction
Muckenthaler et al describe a novel form of hemochromatosis caused by a constitutional PIGA mutation in 3 children with associated neurologic dysfunction. Hemochromatosis results from decreased hepcidin, which is regulated by HFE, hemojuvelin (HJV), and transferrin receptor 2. HJV is a glycosylphosphatidylinositol-linked protein, so PIGA mutation leads to decreased HJV expression. Interestingly, none of the children had evidence of paroxysmal nocturnal hemoglobinuria. The cause of the novel association with central nervous system manifestations remains to be elucidated.
- 1 July 2021
- Published by Elsevier in Seminars in Hematology
- Vol. 58 (3) , 132-144
20 years of Hepcidin: How far we have come
- 1 July 2021
- Published by Elsevier in Seminars in Hematology
- Vol. 58 (3) , 132-144
20 years of Hepcidin: How far we have come
- Open Access
- 16 June 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (19) , 2100385
Core Cross‐Linked Polymeric Micelles for Specific Iron Delivery: Inducing Sterile Inflammation in Macrophages
Iron is an essential co‐factor for cellular processes. In the immune system, it can activate macrophages and represents a potential therapeutic for various diseases. To specifically deliver iron to macrophages, iron oxide nanoparticles are embedded in polymeric micelles of reactive polysarcosine‐block‐poly(S‐ethylsulfonyl‐l‐cysteine). Upon surface functionalization via dihydrolipoic acid, iron oxide cores act as crosslinker themselves and undergo chemoselective disulfide bond formation with the surrounding poly(S‐ethylsulfonyl‐l‐cysteine) block, yielding glutathione‐responsive core cross‐linked polymeric micelles (CCPMs). When applied to primary murine and human macrophages, these nanoparticles display preferential uptake, sustained intracellular iron release, and induce a strong inflammatory response. This response is also demonstrated in vivo when nanoparticles are intratracheally administered to wild‐type C57Bl/6N mice. Most importantly, the controlled release concept to deliver iron oxide in redox‐responsive CCPMs induces significantly stronger macrophage activation than any other iron source at identical iron levels (e.g., Feraheme), directing to a new class of immune therapeutics.
- 16 June 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (19) , 2100385
Open AccessCore Cross‐Linked Polymeric Micelles for Specific Iron Delivery: Inducing Sterile Inflammation in Macrophages
Iron is an essential co‐factor for cellular processes. In the immune system, it can activate macrophages and represents a potential therapeutic for various diseases. To specifically deliver iron to macrophages, iron oxide nanoparticles are embedded in polymeric micelles of reactive polysarcosine‐block‐poly(S‐ethylsulfonyl‐l‐cysteine). Upon surface functionalization via dihydrolipoic acid, iron oxide cores act as crosslinker themselves and undergo chemoselective disulfide bond formation with the surrounding poly(S‐ethylsulfonyl‐l‐cysteine) block, yielding glutathione‐responsive core cross‐linked polymeric micelles (CCPMs). When applied to primary murine and human macrophages, these nanoparticles display preferential uptake, sustained intracellular iron release, and induce a strong inflammatory response. This response is also demonstrated in vivo when nanoparticles are intratracheally administered to wild‐type C57Bl/6N mice. Most importantly, the controlled release concept to deliver iron oxide in redox‐responsive CCPMs induces significantly stronger macrophage activation than any other iron source at identical iron levels (e.g., Feraheme), directing to a new class of immune therapeutics.
- Open Access
- 13 May 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (4) , 2186-2200
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation
Background and Aims: TGFβ/bone morphogenetic protein (BMP) signaling in the liver plays a critical role in liver disease. Growth factors, such as BMP2, BMP6, and TGFβ1, are released from LSECs and signal in a paracrine manner to hepatocytes and hepatic stellate cells to control systemic iron homeostasis and fibrotic processes, respectively. The misregulation of the TGFβ/BMP pathway affects expression of the iron‐regulated hormone hepcidin, causing frequent iron overload and deficiency diseases. However, whether LSEC‐secreted factors can act in an autocrine manner to maintain liver homeostasis has not been addressed so far. Approach and Results: We analyzed publicly available RNA‐sequencing data of mouse LSECs for ligand‐receptor interactions and identified members of the TGFβ family (BMP2, BMP6, and TGFβ1) as ligands with the highest expression levels in LSECs that may signal in an autocrine manner. We next tested the soluble factors identified through in silico analysis in optimized murine LSEC primary cultures and mice. Exposure of murine LSEC primary cultures to these ligands shows that autocrine responses to BMP2 and BMP6 are blocked despite high expression levels of the required receptor complexes partially involving the inhibitor FK‐506–binding protein 12. By contrast, LSECs respond efficiently to TGFβ1 treatment, which causes reduced expression of BMP2 through activation of activin receptor‐like kinase 5. Conclusions: These findings reveal that TGFβ1 signaling is functionally interlinked with BMP signaling in LSECs, suggesting druggable targets for the treatment of iron overload diseases associated with deficiency of the BMP2‐regulated hormone hepcidin, such as hereditary hemochromatosis, β‐thalassemia, and chronic liver diseases.
- 13 May 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (4) , 2186-2200
Open AccessLiver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation
Background and Aims: TGFβ/bone morphogenetic protein (BMP) signaling in the liver plays a critical role in liver disease. Growth factors, such as BMP2, BMP6, and TGFβ1, are released from LSECs and signal in a paracrine manner to hepatocytes and hepatic stellate cells to control systemic iron homeostasis and fibrotic processes, respectively. The misregulation of the TGFβ/BMP pathway affects expression of the iron‐regulated hormone hepcidin, causing frequent iron overload and deficiency diseases. However, whether LSEC‐secreted factors can act in an autocrine manner to maintain liver homeostasis has not been addressed so far. Approach and Results: We analyzed publicly available RNA‐sequencing data of mouse LSECs for ligand‐receptor interactions and identified members of the TGFβ family (BMP2, BMP6, and TGFβ1) as ligands with the highest expression levels in LSECs that may signal in an autocrine manner. We next tested the soluble factors identified through in silico analysis in optimized murine LSEC primary cultures and mice. Exposure of murine LSEC primary cultures to these ligands shows that autocrine responses to BMP2 and BMP6 are blocked despite high expression levels of the required receptor complexes partially involving the inhibitor FK‐506–binding protein 12. By contrast, LSECs respond efficiently to TGFβ1 treatment, which causes reduced expression of BMP2 through activation of activin receptor‐like kinase 5. Conclusions: These findings reveal that TGFβ1 signaling is functionally interlinked with BMP signaling in LSECs, suggesting druggable targets for the treatment of iron overload diseases associated with deficiency of the BMP2‐regulated hormone hepcidin, such as hereditary hemochromatosis, β‐thalassemia, and chronic liver diseases.